Testing effectiveness (Phase 2)Ended earlyNCT01160445
What this trial is testing
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
Who this might be right for
Metastatic MelanomaMetastatic Renal Cancer
National Cancer Institute (NCI) 9